Novo Nordisk Patent for IL-6 Antagonist Treatment of Diuretic Resistant Heart Failure
Summary
The USPTO granted Patent US12600773B2 to Novo Nordisk A/S on April 14, 2026, covering methods of treating diuretic resistant heart failure patients carrying at least one copy of the TMPRSS6 rs855791 allele by administering an IL-6 antagonist. The patent also covers treatment of patients with elevated urine or plasma IL-6 levels requiring diuresis. The patent (CPC: C07K 16/248) names five inventors and issues from Application No. 17519082 filed November 4, 2021, with 10 claims granted.
What changed
USPTO granted Patent US12600773B2 to Novo Nordisk A/S, covering methods of treating diuretic resistance in heart failure patients who carry at least one copy of the TMPRSS6 rs855791 allele using an IL-6 antagonist. The patent also extends to patients exhibiting elevated IL-6 levels in urine, plasma, or both. The patent issued from Application No. 17519082 (filed November 4, 2021) and includes 10 claims under CPC classification C07K 16/248.
Pharmaceutical companies and biotechnology firms developing IL-6 targeted therapies for heart failure or diuretic resistance should monitor this patent when designing clinical programs or filing related patents. Competitors may need to consider licensing strategies or design-around approaches to avoid infringement. Researchers studying TMPRSS6 genetic markers in cardiac or renal disease contexts should be aware of the newly established intellectual property landscape.
What to do next
- Monitor for potential licensing or collaboration opportunities
- Review pipeline for products targeting IL-6 signaling in heart failure
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele
Grant US12600773B2 Kind: B2 Apr 14, 2026
Assignee
Novo Nordisk A/S
Inventors
Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
Abstract
The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
CPC Classifications
C07K 16/248 C07K 2317/76 A61P 13/12 A61P 7/10
Filing Date
2021-11-04
Application No.
17519082
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.